1 |
Lee JA, Oh J, Moon S, Lim JT, Lee JS, Lee JY, Kim Y. Assessment of needs and accessibility towards health insurance claims data. Korean J Health Policy Admin 2011;21(1):77-92.
DOI
ScienceOn
|
2 |
Health Insurance Review and Assessment Service. Drug list and tariff [Internet]. Seoul: Health Insurance Review and Assessment Service; 2010 [cited 2012 Jul 11]. Available from: http://www.hira.or.kr.
|
3 |
Jung SW, Lee TJ, Cho BH. Market competition structure after original drug patent expiry. Korean J Health Econ Policy 2008;14(2):1-25.
|
4 |
Park SV. Risk-sharing agreement on the pricing and reimbursement of new drugs. Korean J Health Econ Policy 2010;16(2):125-153.
|
5 |
Lee SM, Kim NS. The development research on a prescribing incentive model to reduce priscribing cost in the health insurance system. Korean J Health Econ Policy 2010;16(3):63-89.
|
6 |
Kwon HY, Yang BM. Fixed budget for pharmaceuticals. Korean J Health Econ Policy 2011;17(1):25-45.
|
7 |
Health Insurance Review and Assessment Service. The results of clinical effectiveness and cost-effectiveness of hyperlipidemia treatments. Seoul: Health Insurance Review and Assessment Service; 2009.
|
8 |
Kim D, Kim N, Lee S. Determination of defined daily dose of medicines using nominal group technique and analysis of antibiotics use in national insurance claim data: focused on antibiotics without DDD of WHO. Korean J Clin Pharm 2007;17(1):19-32.
|
9 |
Meng Q, Cheng G, Silver L, Sun X, Rehnberg C, Tomson G. The impact of China's retail drug price control policy on hospital expenditures: a case study in two Shandong hospitals. Health Policy Plan 2005;20(3):185-196.
DOI
ScienceOn
|
10 |
Yang BM, Bae EY, Kim J. Economic evaluation and pharmaceutical reimbursement reform in South Korea's National Health Insurance. Health Aff (Millwood) 2008;27(1):179-187.
DOI
ScienceOn
|
11 |
Bae EY, Lee EK. Pharmacoeconomic guidelines and their implementation in the positive list system in South Korea. Value Health 2009;12 Suppl 3:S36-S41.
|
12 |
Bae EY. Challenges in drug re-evaluation system based on health technology assessment. Korean J Health Econ Policy 2010;16(3):163-187.
|
13 |
Bae EY. Study on the drug expenditure trend in Korea. Korean J Health Econ Policy 2007;13(2):39-54.
|
14 |
Choi YJ, Shalowitz JI. Major growths of Korean pharmaceutical expenditure. J Korea Soc Health Inform Stat 2011;36(1):15-24.
|
15 |
Kim YS, Kim SO. Analysis of the factors associated increased pharmaceutical expenditure and its management policies. Seoul: National Health Insurance Service; 2009.
|
16 |
Ess SM, Schneeweiss S, Szucs TD. European healthcare policies for controlling drug expenditure. Pharmacoeconomics 2003;21(2):89-103.
DOI
ScienceOn
|
17 |
Jang SM, Park CM, Bae GR, Lee HJ, Kim HS. Analysis of the factors related to the pharmaceutical expenditure of the National Health Insurance. Seoul: Health Insurance Review and Assessment Service; 2010.
|
18 |
Kwon HY, Yang BM. Drug mix effect of newly reimbursed drugs on pharmaceutical expenditures. Korean J Health Econ Policy 2011;17(2):151-169.
|
19 |
Kwon HY, Yang BM. Do generics really create savings on drug expenditures? Korean J Health Econ Policy 2011;17(4):23-42.
|
20 |
Organization for Economic Cooperation and Development. Pharmaceutical expenditure [Internet]. Paris: Organization for Economic Cooperation and Development; 2012 [cited 2012 Jul 5]. Available from: http://www.oecd.org/health/healthdata.
|
21 |
National Health Insurance Service. National health insurance statistical yearbook: 2010 pharmacy prescription data [Internet]. Seoul: National Health Insurance Service; 2010 [cited 2012 Dec 28]. Available from: http://www.nhic.or.kr.
|
22 |
IMS Health. Top 20 global therapeutic classes, 2010: total audited markets [Internet]. Danbury (CT): IMS Health; 2010 [cited 2012 Jul 5]. Available from: http://www.imshealth.com.
|
23 |
Shin SY, Song HJ, Jang SM, Sung YN. Development of the outcome index of hyperlipidemia treatments (lipid lowering agents). Seoul: Health Insurance Review and Assessment Service; 2009.
|
24 |
Mrazek MF. Comparative approaches to pharmaceutical price regulation in the European Union. Croat Med J 2002;43(4):453-461.
|
25 |
Maynard A, Bloor K. Dilemmas in regulation of the market for pharmaceuticals. Health Aff (Millwood) 2003;22(3):31-41.
DOI
|